Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB01030_DB01259_nanopub.RAtDtFj27P_IK27mIxnebqPG6IX8-1lqIXyu-wkAgMeDg#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB01030_DB01259 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB01030_DB01259 label "DDI between Topotecan and Lapatinib - The p-glycoprotein inhibitor, Lapatinib, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. [drugbank_resource:DB01030_DB01259]" assertion.
- drugbank_resource:DB01030_DB01259 identifier "drugbank_resource:DB01030_DB01259" assertion.
- drugbank_resource:DB01030_DB01259 title "DDI between Topotecan and Lapatinib - The p-glycoprotein inhibitor, Lapatinib, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided." assertion.
- drugbank:DB01030 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB01030_DB01259 assertion.
- drugbank:DB01259 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB01030_DB01259 assertion.